Northwest Biotherapeutics (NWBO) Accumulated Expenses (2010 - 2017)

Northwest Biotherapeutics' Accumulated Expenses history runs 8 years deep, the most recent figure standing at $933000.0 for Q1 2017.

• In Q1 2017, Accumulated Expenses fell 21.53% year-over-year to $933000.0; the TTM figure through Mar 2017 stood at $933000.0 (down 21.53% YoY), while the FY2016 annual figure was $901000.0, down 31.17% from the prior year.
• Accumulated Expenses for Q1 2017 stood at $933000.0, up from $901000.0 in the prior quarter.
• The five-year high for Accumulated Expenses was $1.3 million in Q2 2016, with the low at $655000.0 in Q2 2014.
• The 5-year median for Accumulated Expenses is $1.1 million (2013), against an average of $1.0 million.
• The sharpest annual moves came in 2013 and 2015: Accumulated Expenses tumbled 85.71% in 2013, then surged 81.37% in 2015.
• Northwest Biotherapeutics' Accumulated Expenses stood at $842000.0 in 2013, then soared by 43.82% to $1.2 million in 2014, then climbed by 8.09% to $1.3 million in 2015, then slumped by 31.17% to $901000.0 in 2016, then increased by 3.55% to $933000.0 in 2017.
• Business Quant data shows NWBO's Accumulated Expenses at $933000.0 in Q1 2017, $901000.0 in Q4 2016, and $1.3 million in Q3 2016.